U.S. Stock Futures Steady as Wall Street Eyes Bank Earnings Amid Iran Tensions 
Colombia Softens 100% Tariff on Ecuador With Smart Subsidies 
China's Trade Surplus Shrinks Sharply in March Amid AI Import Surge and Export Slowdown 
Gold Prices Slip as Strait of Hormuz Blockade Fuels Risk-On Sentiment 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Spain's Sanchez Visits China to Deepen Trade Ties Amid U.S. Tensions 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Asia FX Weekly Gains Hold Amid U.S. Inflation Data and Iran Ceasefire Uncertainty 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
Food prices are already high in Canada. Will the Iran war make them worse? 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
U.S. Markets Post Strong Weekly Gains Despite Middle East Tensions and Rising Energy Prices 
Oil Prices Drop Amid U.S. Blockade on Iran and Ceasefire Uncertainty 
Samsung Biologics and Samsung C&T are investing in Araris Switzerland-based biotech company. The former announced on Wednesday, April 12, that it would be joining in the series A funding round for the said Swiss firm.
Arais Biotech AG is a company that makes antibody-drug conjugate (ADC) technologies. This refers to a type of medicine formulated as a targeted therapy for the treatment of cancer.
Samsung Biologics is the contract manufacturing arm of the Samsung Group, and it has confirmed its participation in the funding round to secure a stake in the Swiss ADC company. As per The Korea Herald, it will be making its investments in Araris through Samsung Life Science Fund, which is being co-managed by Samsung Biologics and Samsung C&T.
The fund is said to be worth around KRW150 billion or $113 million, and it was set up in 2021 to support Samsung Biologics' bid to find new business opportunities in the global biotech industry.
It was said that the undisclosed amount of investment funds would be primarily used to back Araris in its works for the development of potential candidates for ADCs. The value of the fund was not shared with the public because of the agreements made between Samsung Biologics and Araris.
The South Korean biotech firm added that through this new investment, it is aiming to expand its ADC-related portfolio as well. It will also be able to actively participate in the production of ADC drugs through its partnership with Araris.
“Araris has the potential to develop best-in-class ADC therapies, and we see room for collaboration in the manufacturing and development of new drugs,” Samsung Biologics’ president and chief executive officer, John Rim, said in a statement.
Araris Biotech’s CEO and co-founder, Philipp Spycher, Ph.D., added, “We are pleased to receive this support from Samsung, as well as the recognition of the potential of our linker-payload toolbox and conjugation technology in such a quickly growing ADC field and we look forward to using these proceeds to further support our efforts in advancing our ADC candidates toward the clinic.”
